Carmen Jungbäck
IABS-EU, Germany
Klaus-Peter Behr
Anicon, Germany
Gerfried Zeller
European Manufacturers of Autogenous Vaccines & Sera (EMAV), Germany
Peter Schmid
CEVA, Germany
Dušan Palić
Ludwig Maximilian University of Munich, Germany
Vaughn Kubiak
IABS, France
Jiři Bures
Institute for State Control of Veterinary Biologicals and Medicines, Czech Republic
Mariette Salery
ANSES-ANMV, France
Jason Todd
Veterinary Medicines Directorate (VMD), United Kingdom
Natalie Vasallo
Labocea, France
Maarten De Gussem
Poulpharm, Belgium
Iska Lehmann
LAVES, Germany
Santiago Cabaleiro
CETGA, Spain
Max Bastian
FLI, Germany
Klaus-Peter Behr
EMAV, Germany
Wiebke Bielenberg
Anicon, Germany
Rosario Bullido
AEMPS, Spain
Jiri Bures
USKVBL, Czech Republic
Santiago Cabaleiro
CETGA, Spain
Rory Cooney
VMD, United Kingdom
Maarten De Gussem
Poulpharm, Belgium
Jean de Foucault
Biovac-CEVA, France
Ernö Horvath
NEBIH, Hungary
David John
AHE, Belgium
Dietmar Katinger
BS-Immun, Austria
Vaughn Kubiak
IABS, France
Aline Lefebvre
COOPERL, France
Iska Lehmann
LAVES, Germany
Jordi Lopez
FEADSA, Spain
Celine Lorteau
ANSES-ANMV, France
Brigitte Othmar-Vielitz
Vaxxinova, Germany
Dušan Palić
LMU, Germany
Mariette Salery
ANSES-ANMV, Frace
Peter Schmid
CEVA, Germany
Annie Sigognault-Flochlay
Filavie, France
Jason Todd
VMD, United Kingdom
Nathalie Vasallo
LABOCEA, France
Ewald Van Kuppeveld
Ripac, Germany
Gregory Verdier
ANSES-ANMV, France
Gerfried Zeller
EMAV, Germany

In the process of implementation of REGULATION (EU) 2019/6 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC members of the association of European Manufacturers of Autogenous Vaccines and Sera – EMAV - have compiled common positions for a dedicated GMP Annex for Autogenous vaccines. This proposal defines future standards for the production of Autogenous vaccines to preserve their quality without hindering their manufacturing and availability.

This position paper is an invitation of EMAV to competent authorities, users and other stakeholders to define a new standard for manufacturing and for a secured availability of Autogenous vaccines in the future.

This position paper would become part of the workshop “AUTOGENOUS VACCINES: QUALITY OF PRODUCTION AND MOVEMENT IN A COMMON MARKET”, organized by EMAV and IABS for September 14th – 16th as a hybrid meeting at Munich University LMU too.

The results of the scientific excursus will be incorporated in a IABS – EMAV meeting report and will be shared with all participants of the workshop and all people interested in.

Download the position paper: https://www.emav.be/position-papers

The e-Book will be available soon!

The Meeting Slides will be available soon! test

This conference is co-organized by the International Alliance for Biological Standardization Europe (IABS-EU) and the European Manufacturers of Autogenous Vaccines & Sera (EMAV).

For further information: